Jump to ContentJump to Main Navigation
India and the Patent WarsPharmaceuticals in the New Intellectual Property Regime$
Users without a subscription are not able to see the full content.

Murphy Halliburton

Print publication date: 2017

Print ISBN-13: 9781501713460

Published to Cornell Scholarship Online: September 2018

DOI: 10.7591/cornell/9781501713460.001.0001

Show Summary Details
Page of

PRINTED FROM Cornell University Press SCHOLARSHIP ONLINE (www.cornell.universitypressscholarship.com). (c) Copyright University of Cornell University Press, 2021. All Rights Reserved. An individual user may print out a PDF of a single chapter of a monograph in Cornell for personal use. date: 04 August 2021

Conclusion

Conclusion

Chapter:
(p.140) Conclusion
Source:
India and the Patent Wars
Author(s):

Murphy Halliburton

Publisher:
Cornell University Press
DOI:10.7591/cornell/9781501713460.003.0007

The conclusion reiterates the problems with analyzing this new constellation of power and of predicting its outcomes. Certain effective provisions are highlighted such as Section 3d of India’s new Patents Act which maintains rigorous standards of inventiveness and efficacy, preventing the “evergreening” of patents and “me too” drugs that have been awarded patents elsewhere. The study ends with a brief comparison to similar patent struggles in Brazil and an assessment of programs that offer more equitable approaches to innovation and ownership such as the Health Impact Fund and the Open Source Drug Discovery program.

Keywords:   power, resistance, Brazil, Health Impact Fund, Open Source Drug Discovery program

Cornell Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us.